Sugammadex for the reversal of muscle relaxation in general anaesthesia: A systematic review and economic assessment.

Sasmita  Soren; Manisha  Tirkey; Shyam Charan  Baskey

doi:10.51168/sjhrafrica.v6i5.1957

Authors

Sasmita Soren Assistant Professor, Department of Anaesthesiology, Medinirai Medical College & Hospital, Palamu, Jharkhand, India
Manisha Tirkey Assistant Professor, Department of Anaesthesiology, Medinirai Medical College & Hospital, Palamu, Jharkhand, India
Shyam Charan Baskey Associate Professor, Department of Surgery, Medinirai Medical College & Hospital, Palamu, Jharkhand, India

DOI:

https://doi.org/10.51168/sjhrafrica.v6i5.1957

Keywords:

Sugammadex, Neuromuscular Blockade, General Anaesthesia, Cost-effectiveness

Abstract

Background

For intubation and surgical optimisation, general anaesthesia requires neuromuscular blocking agents (NMBAs). Sugammadex, a new reversal drug, reverses Aminosteroidal-induced neuromuscular blockade quickly and predictably, improving patient outcomes and operating room efficiency.

Objectives

To evaluate the clinical effectiveness and economic viability of sugammadex compared to neostigmine or placebo for the reversal of rocuronium- or vecuronium-induced neuromuscular blockade in general anaesthesia.

Methods

A comprehensive review compared sugammadex to neostigmine or placebo for reversing moderate, profound, and acute neuromuscular blockade. Recovery timeframes, safety, and economic impacts were collected. A de novo cost-effectiveness model based on UK NHS practice assessed the value per minute of recuperation time saved.

Results

Sugammadex shortened recovery times by 1.3–1.7 minutes (moderate blockade) and 2.7 minutes (deep blockade) compared to neostigmine and placebo. Economic studies showed that sugammadex might be cost-effective if operating room recovery time savings were over £2.40 per minute. The safety profile was better than neostigmine.

Conclusion

Sugammadex is a clinically effective and potentially cost-efficient agent for NMB reversal. Its advantages are especially relevant in high-turnover or high-risk surgical settings, though broader economic assessments across healthcare systems are needed.

References

Naguib M, Brull SJ, Hunter JM. Comparative pharmacology of neuromuscular blocking drugs. In: Miller RD, Cohen NH, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL, editors. Miller’s Anesthesia. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 995–1014.

Plaud B, Merle JC, Debaene B. Sugammadex: a short review of its clinical use. Ann Fr Anesth Reanim. 2010;29(12):909–916. doi:10.1016/j.annfar.2010.07.006

Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth. 2006;97(2):123–126. doi:10.1093/bja/ael187

Chambers D, Paulden M, Paton F, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess. 2010;14(39):1–211. doi:10.3310/hta14390

Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104(4):667–674. doi:10.1097/00000542-200604000-00011

Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults: a Cochrane systematic review with meta-analysis. Anaesthesia. 2018;73(6):631–641. doi:10.1111/anae.14160

Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane or propofol anesthesia: results from a randomized, controlled trial. Eur J Anaesthesiol. 2010;27(10):874–881. doi:10.1097/EJA.0b013e32833f2602

Naguib M, Brull SJ, Kopman AF, et al. Consensus Statement on Perioperative Use of Neuromuscular Monitoring. Anesth Analg. 2018;127(1):71–80. doi:10.1213/ANE.0000000000002670

Cammu G. Residual neuromuscular blockade and postoperative pulmonary complications: what does the recent evidence demonstrate? Curr Anesthesiol Rep. 2020;10(2):142–147. doi:10.1007/s40140-020-00386-8

Carron M, Zarantonello F, Lazzarotto N, Tellaroli P, Ori C. Sugammadex compared with neostigmine/glycopyrrolate for reversal of neuromuscular block: a meta-analysis of randomized controlled trials. Eur J Anaesthesiol. 2016;33(11):774–783. doi:10.1097/EJA.0000000000000493

Hristovska AM, Duch P, Allingstrup M, Afshari A. A Cochrane systematic review and meta-analysis of sugammadex and neostigmine in reversing neuromuscular blockade in adults. Anaesthesia. 2018. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/abs/10.1111/anae.14160

Liu HM, Yu H, Zuo YD, Liang P. Postoperative pulmonary complications after sugammadex reversal of neuromuscular blockade: a systematic review and meta-analysis. BMC Anesthesiology. 2023. https://link.springer.com/article/10.1186/s12871-023-02094-0

Subramani Y, Querney J, He S. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in morbidly obese adult patients: a systematic review. Anaesthesia Reports. 2021. https://journals.lww.com/anar/fulltext/2021/15010/Efficacy_and_Safety_of_Sugammadex_versus.19.aspx

Won YJ, Lim BG, Lee DK, et al. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: a systematic review and meta-analysis. Medicine (Baltimore). 2016. https://journals.lww.com/md-journal/fulltext/2016/08230/Sugammadex_for_reversal_of_rocuronium_induced.49.aspx

Chambers D, Paulden M, Paton F. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess. 2010. https://journalslibrary.nihr.ac.uk/hta/HTA14390